Beleave Inc. announced the appointment of Mark Heselton and Mark Miles to the company's Board of Directors. Mark Heselton is an experienced pharmaceutical executive with more than 25 years with Fortune 100, NYSE listed, research-based pharmaceutical companies including Bristol-Myers Squibb, Merck and Pfizer. He is currently Senior Vice President, Global Partner Business with Vifor Pharmaceuticals, the world's leading iron replacement therapy company, based in Zurich, Switzerland. In addition, Mark Miles is the President of M2PM Limited and has more than thirty-five years of experience and expertise in the construction and development industries.